Creation of waterproof, TLD probes for dose measurements to validate image-based radiopharmaceutical therapy dosimetry workflow.
David P AdamClifford HammerJulia Ziege MalyshevWesley S CulbersonTyler James BradshawJoseph GrudzinskiPaul M HarariBryan P BednarzPublished in: Biomedical physics & engineering express (2023)
Voxel-level dosimetry based on nuclear medicine images offers patients the most personalized form of radiopharmaceutical therapy (RPT) treatments. Clinical evidence is emerging demonstrating improvements in treatment precision in patients when voxel-level dosimetry is used. Voxel-level dosimetry requires absolute quantification of activity concentrations in the patient, but images from SPECT/CT scanners are not quantitative and require calibration using nuclear medicine phantoms. While phantom studies can validate a scanner's ability to recover activity concentrations, this is only a surrogate for the true metric of interest: absorbed doses. Measurements using thermoluminescent dosimeters (TLDs) are a versatile and accurate method of measuring absorbed dose. In this work, a TLD probe was manufactured that can fit into currently available nuclear medicine phantoms for the measurement of absorbed dose of RPT agents. Next, 748 MBq of I-131 was administered to a 16 ml hollow source sphere placed in a 6.4 L Jaszczak phantom in addition to six TLD probes, each holding 4 TLD-100 1 x 1 x 1 mm TLD-100 (LiF:Mg,Ti) microcubes. The phantom then underwent a SPECT/CT scan in accordance with a standard SPECT/CT imaging protocol for I-131. The SPECT/CT images were then input into a Monte Carlo based RPT dosimetry platform named RAPID and a three dimensional dose distribution in the phantom was estimated. Additionally, a GEANT4 benchmarking scenario (denoted 'idealized') was created using a stylized representation of the phantom. There was good agreement for all six probes, the differences between measurement and RAPID ranged between -5.5% and 0.9%. The difference between the measured and the idealized GEANT4 scenario was calculated and ranged from -4.3% and -20.5%. This work demonstrates good agreement between TLD measurements and RAPID. In addition, it introduces a novel TLD probe that can be easily introduced into clinical nuclear medicine workflows to provide QA of image-based dosimetry for RPT treatments.
Keyphrases
- monte carlo
- image quality
- dual energy
- computed tomography
- deep learning
- end stage renal disease
- living cells
- ejection fraction
- newly diagnosed
- small molecule
- chronic kidney disease
- high resolution
- contrast enhanced
- prognostic factors
- pet ct
- optical coherence tomography
- fluorescence imaging
- positron emission tomography
- magnetic resonance imaging
- peritoneal dialysis
- stem cells
- randomized controlled trial
- single molecule
- mesenchymal stem cells
- magnetic resonance
- mass spectrometry
- case control